Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jul 1;106(7):1781-1782.
doi: 10.3324/haematol.2020.278077.

A chemotherapy-free regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia: are we there yet?

Yishai Ofran  1
Affiliations
Editorial

A chemotherapy-free regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia: are we there yet?

Yishai Ofran. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Response after intensive and non-intensive induction in a population of Philadelphia chromosome-positive acute lymphoblastic leukemia patients. (A) Distribution of response levels after intensive induction. (B) Distribution of response levels after non-intensive induction. The distribution of the actual depth of response across patients who achieved minimal residual disease negativity following intensive and non-intensive induction differs and so does the risk of relapse.
See this image and copyright information in PMC

Comment on

References

    1. Vignetti M, Fazi P, Cimino G, et al. . Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676-3678. - PubMed
    1. Foa R, Vitale A, Vignetti M, et al. . Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521-6528. - PubMed
    1. Chiaretti S, Ansuinelli M, Vitale A, et al. . A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients. Final results of the GIMEMA LAL 1509 protocol. Haematologica. 2021;106(7):1828-1838. - PMC - PubMed
    1. FDA Guidance Document: Hematologic Malignancies: Regulatory Considerations for use of minimal residual disease in development of drug and biological products for treatment. Available at https://www.fda.gov/media/134605/download. Accessed in December, 2020.
    1. Short NJ, Jabbour E, Sasaki K, et al. . Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504-507. - PMC - PubMed

MeSH terms

LinkOut - more resources